Myasthania Gravis Treatment Market

Global Myasthenia Gravis Treatment Market by Treatments (Medication, Surgery, and Others), End-users (Hospitals, Clinics, and Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and E-commerce Websites), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) Forecast, 2017-2027

  • Report ID: HC-186
  • Author: Growth Market Reports
  • Rating: 4.2
  • Total Reviews: 6
  • No. Of Pages: 150
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global myasthenia gravis treatment market is anticipated to expand at a substantial CAGR during forecast period, between 2020 and 2027. Myasthenia gravis (MG) is a long term neuromuscular disease in which voluntary muscles easily become weak and tired owing to the problems associated with the contraction of muscles. This autoimmune disease causes weakness in the muscles that are responsible for functions such as breathing and moving parts of the body. Most of the cases of myasthenia gravis are mild, and life expectancy is normal. The symptoms of MG improve after resting and worsen with physical activity.

Symptoms of myasthenia gravis include ocular myasthenia, ptosis, diplopia, dysarthria, and difficulty in swallowing. No definite treatmentsare available for MG. However, treatments with cholinesterase inhibitors or immunosuppressant can help control the symptoms of MG. The cholinesterase inhibitors assist patients in improving communication between muscles and nerves. These inhibitors are effective in patients with mild symptoms of MG.


Market Trends, Drivers, Restraints, and Opportunities:

  • Increase in per capita income across the globe and rise in healthcare expenditure are propelling the myasthenia gravis treatment market.
  • Growth in the occurrence of MG globally and surge in the number of research & development activities are driving the market.
  • High cost associated with the treatment of MG and side effects of intravenous immunoglobulin (IVIG) preparations including sudden cough, muscle cramps, flushing, nausea, vomiting, back/joint pain, chills, fever, chest pain, and wheezingare restraining the market growth.
  • Increase in focus of governments in developing countries on improving healthcare infrastructure is likely to create opportunities in the IVIG treatments and monoclonal antibodies, thereby fueling the global market.


Scope of the report:

The report on myasthenia gravis treatmentmarket includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Attributes

Details

Base Year

2019

Historic Data

2017–2018

Forecast Period

2020–2027

Regional Scope

Asia Pacific, North America, Europe, Latin America, and Middle East & Africa

Report Coverage

Market Scope, Analysis, Share, Competitive Analysis, Growth Facts, Restraints, Opportunities and Revenue Forecast

 

Myasthenia Gravis TreatmentMarket Segment Insights:

High demand for medication treatments drives segment growth
In terms of treatments, theglobal myasthenia gravis treatmentmarket can be categorizedas medication, surgery, and others.Medications include immunotherapies such as corticosteroids, Soliris (eculizumab), and immunosuppressive drugs such as Neoral/Sandimmune (cyclosporine) and Prograf (tacrolimus). The medication segment held a dominant share of the market, as medications can easily help manage the symptoms of MG and improvethe immune system.

Access to a large patient pool in hospitals fuels segment growth
On the basis of end-users, the market can be segregated into hospitals, clinics, and others. The hospitals segment is estimated to expand at a high CAGR during the forecast period due to the availability of advanced equipment for treating MG in hospital settings. Moreover, hospitals provide access to a large patient pool, and thus the number of patients visiting hospitals for diagnosis and treatment has increased in the last decade.

Retail pharmacies segment accounts for a dominant share of the market
Based ondistribution channels, the market can be classifiedas hospital pharmacies, retail pharmacies, and e-commerce. The retail pharmaciessegment held a considerable share of the market. In retail pharmacies, pharmacists interact with the patients to provide targeted counseling. This results in a better experience for the customer, and hence most of the people tend to purchase their medications from retail pharmacies.

North America constitutes dominant share of the market
In terms of regions, the global myasthenia gravis treatment market can segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North Americaaccounts for a large share of the marketowing to rising healthcare expenditure, reimbursement policies, and growing research & development activities in the established R&D facilities. Moreover, increasing adoption of monoclonal antibodies and immunotherapies in the US is driving the growth of the market in North America.
 

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Myasthania Gravis Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Myasthania Gravis Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Myasthania Gravis Treatment Market - Supply Chain
  4.5. Global Myasthania Gravis Treatment Market Forecast
     4.5.1. Myasthania Gravis Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Myasthania Gravis Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Myasthania Gravis Treatment Market Absolute $ Opportunity
5. Global Myasthania Gravis Treatment Market Analysis and Forecast by End Users
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by End Users
     5.2.2. Y-o-Y Growth Projections by End Users
  5.3. Myasthania Gravis Treatment Market Size and Volume Forecast by End Users
     5.3.1. Hospitals
     5.3.2. Clinics
     5.3.3. Others
  5.4. Absolute $ Opportunity Assessment by End Users
  5.5. Market Attractiveness/Growth Potential Analysis by End Users
6. Global Myasthania Gravis Treatment Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Myasthania Gravis Treatment Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Myasthania Gravis Treatment Demand Share Forecast, 2019-2026
7. North America Myasthania Gravis Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Myasthania Gravis Treatment Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Myasthania Gravis Treatment Market Size and Volume Forecast by End Users
     7.4.1. Hospitals
     7.4.2. Clinics
     7.4.3. Others
  7.5. Basis Point Share (BPS) Analysis by End Users
  7.6. Y-o-Y Growth Projections by End Users
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Myasthania Gravis Treatment Demand Share Forecast, 2019-2026
8. Latin America Myasthania Gravis Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Myasthania Gravis Treatment Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Myasthania Gravis Treatment Market Size and Volume Forecast by End Users
     8.4.1. Hospitals
     8.4.2. Clinics
     8.4.3. Others
  8.5. Basis Point Share (BPS) Analysis by End Users
  8.6. Y-o-Y Growth Projections by End Users
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Myasthania Gravis Treatment Demand Share Forecast, 2019-2026
9. Europe Myasthania Gravis Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Myasthania Gravis Treatment Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Myasthania Gravis Treatment Market Size and Volume Forecast by End Users
     9.4.1. Hospitals
     9.4.2. Clinics
     9.4.3. Others
  9.5. Basis Point Share (BPS) Analysis by End Users
  9.6. Y-o-Y Growth Projections by End Users
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Myasthania Gravis Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Myasthania Gravis Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Myasthania Gravis Treatment Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Myasthania Gravis Treatment Market Size and Volume Forecast by End Users
     10.4.1. Hospitals
     10.4.2. Clinics
     10.4.3. Others
  10.5. Basis Point Share (BPS) Analysis by End Users
  10.6. Y-o-Y Growth Projections by End Users
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Myasthania Gravis Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Myasthania Gravis Treatment Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Myasthania Gravis Treatment Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Myasthania Gravis Treatment Market Size and Volume Forecast by End Users
     11.4.1. Hospitals
     11.4.2. Clinics
     11.4.3. Others
  11.5. Basis Point Share (BPS) Analysis by End Users
  11.6. Y-o-Y Growth Projections by End Users
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Myasthania Gravis Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Myasthania Gravis Treatment Market: Market Share Analysis
  12.2. Myasthania Gravis Treatment Distributors and Customers
  12.3. Myasthania Gravis Treatment Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)

By Treatments

  • Medication
  • Surgery
  • Others

By End-users

  • Hospitals
  • Clinics
  • Others

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-commerce

By Regions

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East & Africa

Key players in the myasthenia gravis treatment market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals, Plc., Novartis, Pfizer, Inc., AbbVie Inc., F.Hoffmann-La Roche AG, GlaxoSmithKline Plc., Bausch Health Companies Inc., Shire plc, UCB Pharma, Mitsubishi Tanabe Pharma, Immunovant, CuraVac, and AstellasPharma. Collaborations, mergers, acquisitions, agreements, and partnerships are some growth strategies adopted by these players to strengthen their geographical presence.

Buy Report